Molbio Diagnostics Launches 'EDGE' Healthcare Innovation Program

Molvio Diagnostics, a leader in in-house diagnostic diagnostics, has launched 'EDGE,' a state-of-the-art collaborative program dedicated to accelerating gaming therapy technologies. As part of EDGE, Molbio Diagnostics selects high-powered MedTech startups and small and medium-sized companies with innovative solutions in high-sensitivity immunodiagnostics and rapid POC for early cancer detection. With the launch of EDGE, Molvio reinforces its commitment to providing equitable and affordable healthcare by providing highly relevant solutions.

The program's main objective is to help startups overcome significant hurdles in product development, translation and expansion. With Molvio's experience, guidance, and support, participants can use Molbioand's extensive network and expertise to bring innovation to a global audience.

For 12 weeks, selected participants will receive intensive guidance, resources and expertise from Molbio and its team of experts. This will provide an opportunity to secure worldwide development, manufacturing and sales relationships with Molvio. Upon completion of the project, Molbio will work with a small group of participants for future partnerships, including a financial bridge for co development of products, licensing, sales and distribution. The program is developed in a hybrid mode, and each participant receives a personal guide.

Molbio Diagnostics is India's first 'unicorn' in the biotech space. Its real-time PCR microsystem on Truenat technology enables real-time PCR testing in laboratories and field-and-field settings for healthcare professionals worldwide—and offers Placement close to the patient. With Truenat's growing line of tests for infectious diseases, including tuberculosis, COVID-19, HIV, HCV, HBV, HPV, influenza, and more, this rapid and portable technology enables early and appropriate detection at the point of care—the first point of contact.